Here the PolySia-NPs clearly showed reduction in lesion size and macrophage/microglia areas in C57BL/6 mice retinas compared to Blank-NPs and comparable to Eylea, a potent FDA approved anti-VEGF therapy for exudative AMD. Here, VEGFA is linked to age-related macular degeneration.